BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151-2157. [PMID: 17404099 DOI: 10.1158/1078-0432.ccr-06-2746] [Cited by in Crossref: 594] [Cited by in F6Publishing: 358] [Article Influence: 39.6] [Reference Citation Analysis]
Number Citing Articles
1 Zou Q, Chen YF, Zheng XQ, Ye SF, Xu BY, Liu YX, Zeng HH. Novel thioredoxin reductase inhibitor butaselen inhibits tumorigenesis by down-regulating programmed death-ligand 1 expression. J Zhejiang Univ Sci B 2018;19:689-98. [PMID: 30178635 DOI: 10.1631/jzus.B1700219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
2 Xu Y, Cui G, Jiang Z, Li N, Zhang X. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. Oncol Lett 2019;17:2960-8. [PMID: 30854074 DOI: 10.3892/ol.2019.9910] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
3 Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, Brown L, Lewis A, Davies G, Morrow M, Wilkinson RW. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget 2016;7:18508-20. [PMID: 26918344 DOI: 10.18632/oncotarget.7610] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 10.2] [Reference Citation Analysis]
4 Xiao R, Bergin SM, Huang W, Slater AM, Liu X, Judd RT, Lin ED, Widstrom KJ, Scoville SD, Yu J, Caligiuri MA, Cao L. Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype. Cancer Immunol Res 2016;4:488-97. [PMID: 27045020 DOI: 10.1158/2326-6066.CIR-15-0297] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
5 Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008;14:550-9. [PMID: 18986838 DOI: 10.1016/j.molmed.2008.09.010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
6 Xu T, Chai J, Wang K, Jia Q, Liu Y, Wang Y, Xu J, Yu K, Zhao D, Ma J, Fan L, Yan Q, Guo S, Chen G, Chen Q, Xiao H, Liu F, Qi C, Liang R, Li M, Wang Z. Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma. Front Oncol 2021;11:638154. [PMID: 34221962 DOI: 10.3389/fonc.2021.638154] [Reference Citation Analysis]
7 D'Alincourt Salazar M, Manuel ER, Tsai W, D'Apuzzo M, Goldstein L, Blazar BR, Diamond DJ. Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. Oncoimmunology 2016;5:e1160184. [PMID: 27471630 DOI: 10.1080/2162402X.2016.1160184] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
8 Kothari A, Flick MJ. Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2021;22:5138. [PMID: 34066284 DOI: 10.3390/ijms22105138] [Reference Citation Analysis]
9 Feist M, Zhu Z, Dai E, Ma C, Liu Z, Giehl E, Ravindranathan R, Kowalsky SJ, Obermajer N, Kammula US, Lee AJH, Lotze MT, Guo ZS, Bartlett DL. Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Ther 2021;28:98-111. [PMID: 32632271 DOI: 10.1038/s41417-020-0189-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Ehrlich M, Bacharach E. Oncolytic Virotherapy: The Cancer Cell Side. Cancers (Basel) 2021;13:939. [PMID: 33668131 DOI: 10.3390/cancers13050939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Transl Med 2018;16:86. [PMID: 29615076 DOI: 10.1186/s12967-018-1460-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
12 Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res 2012;72:5209-18. [PMID: 22915761 DOI: 10.1158/0008-5472.CAN-12-1187] [Cited by in Crossref: 235] [Cited by in F6Publishing: 158] [Article Influence: 23.5] [Reference Citation Analysis]
13 Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clin Transl Med 2018;7:32. [PMID: 30294755 DOI: 10.1186/s40169-018-0210-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
14 Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou-Gharios G, Nakamura H, Kawashiri S. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol. 2017;50:41-48. [PMID: 27922697 DOI: 10.3892/ijo.2016.3785] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
15 Van Audenaerde JRM, De Waele J, Marcq E, Van Loenhout J, Lion E, Van den Bergh JMJ, Jesenofsky R, Masamune A, Roeyen G, Pauwels P, Lardon F, Peeters M, Smits ELJ. Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget. 2017;8:56968-56979. [PMID: 28915646 DOI: 10.18632/oncotarget.18185] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
16 Luo W, Yang G, Luo W, Cao Z, Liu Y, Qiu J, Chen G, You L, Zhao F, Zheng L, Zhang T. Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. Cancer Cell Int 2020;20:66. [PMID: 32158356 DOI: 10.1186/s12935-020-1147-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
17 Hou YC, Chao YJ, Hsieh MH, Tung HL, Wang HC, Shan YS. Low CD8⁺ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44⁺/CD133⁺ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer. Cancers (Basel) 2019;11:E541. [PMID: 30991694 DOI: 10.3390/cancers11040541] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
18 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
19 Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci 2019;20:E4543. [PMID: 31540286 DOI: 10.3390/ijms20184543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
20 Yang SH, Lu LC, Kao HF, Chen BB, Kuo TC, Kuo SH, Tien YW, Bai LY, Cheng AL, Yeh KH. Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. Oncoimmunology 2021;10:1973710. [PMID: 34595057 DOI: 10.1080/2162402X.2021.1973710] [Reference Citation Analysis]
21 Balan M, Mier y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK, Freeman G, Pal S. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem. 2015;290:8110-8120. [PMID: 25645920 DOI: 10.1074/jbc.m114.612689] [Cited by in Crossref: 81] [Cited by in F6Publishing: 53] [Article Influence: 11.6] [Reference Citation Analysis]
22 Tunger A, Sommer U, Wehner R, Kubasch AS, Grimm MO, Bachmann MP, Platzbecker U, Bornhäuser M, Baretton G, Schmitz M. The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. J Clin Med 2019;8:E1534. [PMID: 31557787 DOI: 10.3390/jcm8101534] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
23 Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023-5039. [PMID: 27574444 DOI: 10.2147/ott.s105862] [Cited by in Crossref: 297] [Cited by in F6Publishing: 192] [Article Influence: 49.5] [Reference Citation Analysis]
24 Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res. 2015;3:399-411. [PMID: 25678581 DOI: 10.1158/2326-6066.cir-14-0215] [Cited by in Crossref: 242] [Cited by in F6Publishing: 171] [Article Influence: 34.6] [Reference Citation Analysis]
25 Del Re M, Vivaldi C, Rofi E, Salani F, Crucitta S, Catanese S, Fontanelli L, Massa V, Cucchiara F, Fornaro L, Capuano A, Fogli S, Vasile E, Danesi R. Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. Cancers (Basel) 2021;13:3738. [PMID: 34359638 DOI: 10.3390/cancers13153738] [Reference Citation Analysis]
26 Liao Y, Chen L, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. Oncotarget 2017;8:30276-87. [PMID: 28415820 DOI: 10.18632/oncotarget.16326] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
27 Torphy RJ, Zhu Y, Schulick RD. Immunotherapy for pancreatic cancer: Barriers and breakthroughs. Ann Gastroenterol Surg 2018;2:274-81. [PMID: 30003190 DOI: 10.1002/ags3.12176] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 15.5] [Reference Citation Analysis]
28 Okurut S, Boulware DR, Olobo J, Meya DB. Landmark clinical observations and immunopathogenesis pathways linked to HIV and Cryptococcus fatal central nervous system co-infection. Mycoses 2020;63:840-53. [PMID: 32472727 DOI: 10.1111/myc.13122] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
29 Zhou C, Che G, Zheng X, Qiu J, Xie Z, Cong Y, Pei X, Zhang H, Sun H, Ma H. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer. J Cancer Res Clin Oncol 2019;145:2663-74. [PMID: 31541338 DOI: 10.1007/s00432-019-03025-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
30 Mkrtichyan M, Najjar YG, Raulfs EC, Liu L, Langerman S, Guittard G, Ozbun L, Khleif SN. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J Immunol 2012;189:2338-47. [PMID: 22837483 DOI: 10.4049/jimmunol.1103085] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
31 Montemagno C, Cassim S, Pouyssegur J, Broisat A, Pagès G. From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2020;21:E4067. [PMID: 32517181 DOI: 10.3390/ijms21114067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Lin H, Liu ZJ. Advances in understanding the immunopathology of gastric cancer. Shijie Huaren Xiaohua Zazhi 2011; 19(32): 3313-3317 [DOI: 10.11569/wcjd.v19.i32.3313] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Heckl SM, Mau F, Senftleben A, Daunke T, Beckinger S, Abdullazade S, Schreiber S, Röcken C, Sebens S, Schäfer H. Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control. Med Sci (Basel) 2021;9:48. [PMID: 34202040 DOI: 10.3390/medsci9030048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Tsukagoshi M, Wada S, Hirono S, Yoshida S, Yada E, Sasada T, Shirabe K, Kuwano H, Yamaue H. Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer. Oncotarget 2018;9:31448-58. [PMID: 30140382 DOI: 10.18632/oncotarget.25837] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Du C, Wang Y. The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp Clin Cancer Res 2011;30:12. [PMID: 21255410 DOI: 10.1186/1756-9966-30-12] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
36 Brouwer TP, Vahrmeijer AL, de Miranda NFCC. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cell Oncol (Dordr) 2021;44:261-78. [PMID: 33710604 DOI: 10.1007/s13402-021-00587-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Shimizu A, Kaira K, Okubo Y, Utsumi D, Yasuda M, Asao T, Nishiyama M, Takahashi K, Ishikawa O. Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma. J Glob Oncol 2017;3:360-9. [PMID: 28831444 DOI: 10.1200/JGO.2016.005843] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
38 Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550. [PMID: 28018338 DOI: 10.3389/fimmu.2016.00550] [Cited by in Crossref: 219] [Cited by in F6Publishing: 226] [Article Influence: 36.5] [Reference Citation Analysis]
39 Xiang X, Yu PC, Long D, Liao XL, Zhang S, You XM, Zhong JH, Li LQ. Prognostic value of PD -L1 expression in patients with primary solid tumors. Oncotarget 2018;9:5058-72. [PMID: 29435162 DOI: 10.18632/oncotarget.23580] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
40 He J, Huo L, Ma J, Zhao J, Bassett RL, Sun X, Ueno NT, Lim B, Gong Y. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 2018;149:253-61. [PMID: 29425258 DOI: 10.1093/ajcp/aqx162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
41 Palsson-McDermott EM, Dyck L, Zasłona Z, Menon D, McGettrick AF, Mills KHG, O'Neill LA. Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors. Front Immunol 2017;8:1300. [PMID: 29081778 DOI: 10.3389/fimmu.2017.01300] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 13.8] [Reference Citation Analysis]
42 Seifert AM, Eymer A, Heiduk M, Wehner R, Tunger A, von Renesse J, Decker R, Aust DE, Welsch T, Reissfelder C, Weitz J, Schmitz M, Seifert L. PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer. Cancers (Basel) 2020;12:E2756. [PMID: 32987956 DOI: 10.3390/cancers12102756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Zhang SS, Tang J, Yu SY, Ma LI, Wang F, Xie SL, Jin L, Yang HY. Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma. Oncol Lett 2015;10:1063-8. [PMID: 26622626 DOI: 10.3892/ol.2015.3274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
44 Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017;8:91779-94. [PMID: 29207684 DOI: 10.18632/oncotarget.21586] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 32.8] [Reference Citation Analysis]
45 Nishimori A, Konnai S, Okagawa T, Maekawa N, Ikebuchi R, Goto S, Sajiki Y, Suzuki Y, Kohara J, Ogasawara S, Kato Y, Murata S, Ohashi K. In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection. PLoS One 2017;12:e0174916. [PMID: 28445479 DOI: 10.1371/journal.pone.0174916] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
46 Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 2014;9:1036-40. [PMID: 24926549 DOI: 10.1097/JTO.0000000000000177] [Cited by in Crossref: 150] [Cited by in F6Publishing: 70] [Article Influence: 21.4] [Reference Citation Analysis]
47 Rahn S, Krüger S, Mennrich R, Goebel L, Wesch D, Oberg HH, Vogel I, Ebsen M, Röcken C, Helm O, Sebens S. POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma. Oncotarget 2019;10:1572-88. [PMID: 30899426 DOI: 10.18632/oncotarget.26705] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
48 Pham TND, Shields MA, Spaulding C, Principe DR, Li B, Underwood PW, Trevino JG, Bentrem DJ, Munshi HG. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers (Basel) 2021;13:440. [PMID: 33503832 DOI: 10.3390/cancers13030440] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Wang M, Wang J, Wang R, Jiao S, Wang S, Zhang J, Zhang M. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation. Commun Biol 2019;2:392. [PMID: 31667366 DOI: 10.1038/s42003-019-0642-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
50 Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 2015;38:1-11. [PMID: 25415283 DOI: 10.1097/cji.0000000000000062] [Cited by in Crossref: 232] [Cited by in F6Publishing: 176] [Article Influence: 33.1] [Reference Citation Analysis]
51 Munir Ahmad S, Martinenaite E, Hansen M, Junker N, Borch TH, Met Ö, Donia M, Svane IM, Andersen MH. PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. Oncoimmunology 2016;5:e1202391. [PMID: 27622072 DOI: 10.1080/2162402X.2016.1202391] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
52 Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94:41-53. [PMID: 23667165 DOI: 10.1189/jlb.1212631] [Cited by in Crossref: 206] [Cited by in F6Publishing: 192] [Article Influence: 22.9] [Reference Citation Analysis]
53 McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016;2:46-54. [PMID: 26562159 DOI: 10.1001/jamaoncol.2015.3638] [Cited by in Crossref: 431] [Cited by in F6Publishing: 460] [Article Influence: 71.8] [Reference Citation Analysis]
54 Hira-Miyazawa M, Nakamura H, Hirai M, Kobayashi Y, Kitahara H, Bou-Gharios G, Kawashiri S. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. Int J Oncol 2018;52:379-88. [PMID: 29345283 DOI: 10.3892/ijo.2017.4221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
55 Messeha SS, Zarmouh NO, Soliman KFA. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. Nutrients 2021;13:1718. [PMID: 34069461 DOI: 10.3390/nu13051718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Gorchs L, Fernández Moro C, Bankhead P, Kern KP, Sadeak I, Meng Q, Rangelova E, Kaipe H. Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells. Front Immunol 2019;10:847. [PMID: 31068935 DOI: 10.3389/fimmu.2019.00847] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
57 Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24:26. [PMID: 28376884 DOI: 10.1186/s12929-017-0329-9] [Cited by in Crossref: 261] [Cited by in F6Publishing: 266] [Article Influence: 52.2] [Reference Citation Analysis]
58 Grant TJ, Hua K, Singh A. Molecular Pathogenesis of Pancreatic Cancer. Prog Mol Biol Transl Sci. 2016;144:241-275. [PMID: 27865459 DOI: 10.1016/bs.pmbts.2016.09.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
59 Mishra DK, Rocha HJ, Miller R, Kim MP. Immune cells inhibit the tumor metastasis in the 4D cellular lung model by reducing the number of live circulating tumor cells. Sci Rep 2018;8:16569. [PMID: 30410108 DOI: 10.1038/s41598-018-34983-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
60 Mei L, Du W, Ma WW. Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. J Gastrointest Oncol. 2016;7:487-494. [PMID: 27284483 DOI: 10.21037/jgo.2016.03.03] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
61 Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008;8:57. [PMID: 18294387 DOI: 10.1186/1471-2407-8-57] [Cited by in Crossref: 143] [Cited by in F6Publishing: 138] [Article Influence: 10.2] [Reference Citation Analysis]
62 Kimbara S, Kondo S. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol 2016; 22(33): 7440-7452 [PMID: 27672267 DOI: 10.3748/wjg.v22.i33.7440] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
63 Liang X, Sun J, Wu H, Luo Y, Wang L, Lu J, Zhang Z, Guo J, Liang Z, Liu T. PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay. Diagn Pathol 2018;13:5. [PMID: 29378617 DOI: 10.1186/s13000-017-0678-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
64 Hirata-Nozaki Y, Ohkuri T, Ohara K, Kumai T, Nagata M, Harabuchi S, Kosaka A, Nagato T, Ishibashi K, Oikawa K, Aoki N, Ohara M, Harabuchi Y, Uno Y, Takei H, Celis E, Kobayashi H. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. J Transl Med 2019;17:207. [PMID: 31221178 DOI: 10.1186/s12967-019-1957-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
65 Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8:e82870. [PMID: 24349382 DOI: 10.1371/journal.pone.0082870] [Cited by in Crossref: 175] [Cited by in F6Publishing: 182] [Article Influence: 19.4] [Reference Citation Analysis]
66 Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T, Akashi K, Takayanagi R, Shiratsuchi M, Ohshima K. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 2015;126:2193-201. [PMID: 26239088 DOI: 10.1182/blood-2015-02-629600] [Cited by in Crossref: 255] [Cited by in F6Publishing: 261] [Article Influence: 36.4] [Reference Citation Analysis]
67 Guo S, Contratto M, Miller G, Leichman L, Wu J. Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World J Clin Oncol 2017; 8(3): 230-240 [PMID: 28638792 DOI: 10.5306/wjco.v8.i3.230] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
68 Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, Chin S, Chung JC, Kim HC, Lee MS, Baek MJ. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Res Treat. 2017;49:246-254. [PMID: 27456947 DOI: 10.4143/crt.2016.066] [Cited by in Crossref: 82] [Cited by in F6Publishing: 92] [Article Influence: 13.7] [Reference Citation Analysis]
69 Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance? Cancer J 2010;16:311-7. [PMID: 20693841 DOI: 10.1097/PPO.0b013e3181eb3381] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
70 Jia L, Zhang Q, Zhang R. PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biol Med. 2018;15:116-123. [PMID: 29951336 DOI: 10.20892/j.issn.2095-3941.2017.0086] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
71 Zhao L, Li C, Liu F, Zhao Y, Liu J, Hua Y, Liu J, Huang J, Ge C. A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco Targets Ther 2017;10:2115-26. [PMID: 28442920 DOI: 10.2147/OTT.S130481] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
72 Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu H, Li H, Luo X, Ye T, Sun Y, Chen H. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 2014;7:567-73. [PMID: 24748806 DOI: 10.2147/OTT.S59959] [Cited by in Crossref: 129] [Cited by in F6Publishing: 107] [Article Influence: 16.1] [Reference Citation Analysis]
73 Rai ZL, Feakins R, Pallett LJ, Manas D, Davidson BR. Irreversible Electroporation (IRE) in Locally Advanced Pancreatic Cancer: A Review of Current Clinical Outcomes, Mechanism of Action and Opportunities for Synergistic Therapy. J Clin Med 2021;10:1609. [PMID: 33920118 DOI: 10.3390/jcm10081609] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Chen Y, Xue SA, Behboudi S, Mohammad GH, Pereira SP, Morris EC. Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients. Clin Cancer Res 2017;23:6178-89. [PMID: 28710313 DOI: 10.1158/1078-0432.CCR-17-1185] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
75 Amedei A, Niccolai E, Prisco D. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother. 2014;10:3354-3368. [PMID: 25483688 DOI: 10.4161/hv.34392] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
76 Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, Wang X, Timmons CL, Hu J, Liu B. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One. 2013;8:e65821. [PMID: 23785454 DOI: 10.1371/journal.pone.0065821] [Cited by in Crossref: 148] [Cited by in F6Publishing: 151] [Article Influence: 16.4] [Reference Citation Analysis]
77 Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the development of cancer immunotherapies. Trends Immunol 2013;34:90-8. [PMID: 23031830 DOI: 10.1016/j.it.2012.08.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
78 Zhu J, Wen H, Ju X, Bi R, Zuo W, Wu X. Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. PLoS One 2017;12:e0170879. [PMID: 28125702 DOI: 10.1371/journal.pone.0170879] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
79 Alfarra H, Weir J, Grieve S, Reiman T. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. Front Immunol 2020;11:575609. [PMID: 33304346 DOI: 10.3389/fimmu.2020.575609] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
80 Zhu X, Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget 2017;8:97671-82. [PMID: 29228642 DOI: 10.18632/oncotarget.18311] [Cited by in Crossref: 124] [Cited by in F6Publishing: 129] [Article Influence: 24.8] [Reference Citation Analysis]
81 Zhu J, Wen H, Bi R, Wu Y, Wu X. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol 2017;28:e77. [PMID: 29027395 DOI: 10.3802/jgo.2017.28.e77] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
82 Yokoyama S, Miyoshi H. Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma. J Thorac Dis 2020;12:7553-60. [PMID: 33447446 DOI: 10.21037/jtd-19-3703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Billon E, Finetti P, Bertucci A, Niccoli P, Birnbaum D, Mamessier E, Bertucci F. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. Oncoimmunology 2019;8:e1655362. [PMID: 31646101 DOI: 10.1080/2162402X.2019.1655362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
84 Dong L, Lv H, Li W, Song Z, Li L, Zhou S, Qiu L, Qian Z, Liu X, Feng L, Meng B, Fu K, Wang X, Pan-Hammarström Q, Wang P, Wang X, Zhang H. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Oncotarget 2016;7:33350-62. [PMID: 27147575 DOI: 10.18632/oncotarget.9061] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
85 Takeuchi M, Miyoshi H, Asano N, Yoshida N, Yamada K, Yanagida E, Moritsubo M, Nakata M, Umeno T, Suzuki T, Komaki S, Muta H, Furuta T, Seto M, Ohshima K. Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma. Haematologica 2019;104:1626-32. [PMID: 30630986 DOI: 10.3324/haematol.2018.205567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
86 Sodergren MH, Mangal N, Wasan H, Sadanandam A, Balachandran VP, Jiao LR, Habib N. Immunological combination treatment holds the key to improving survival in pancreatic cancer. J Cancer Res Clin Oncol 2020;146:2897-911. [PMID: 32748119 DOI: 10.1007/s00432-020-03332-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
87 Xu H, Chen X, Tao M, Chen K, Chen C, Xu G, Li W, Yuan S, Mao Y. B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer. Oncol Lett 2016;11:1841-6. [PMID: 26998087 DOI: 10.3892/ol.2016.4128] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
88 Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res 2014;74:2974-85. [PMID: 24728077 DOI: 10.1158/0008-5472.CAN-13-2564] [Cited by in Crossref: 97] [Cited by in F6Publishing: 67] [Article Influence: 12.1] [Reference Citation Analysis]
89 Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013;19:1021-34. [PMID: 23460533 DOI: 10.1158/1078-0432.CCR-12-2063] [Cited by in Crossref: 327] [Cited by in F6Publishing: 213] [Article Influence: 36.3] [Reference Citation Analysis]
90 Long L, Chen M, Yuan Y, Ming AL, Guo W, Wu K, Chen H. High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma. J Cancer 2020;11:4442-52. [PMID: 32489463 DOI: 10.7150/jca.42610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
91 Liu X, Shan C, Song Y, Du J. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients. Front Oncol 2019;9:1111. [PMID: 31709181 DOI: 10.3389/fonc.2019.01111] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
92 Batman S, Matsuo K, Mhawech-Fauceglia P, Munro E, Weisenberger M, Allen A, Joshi S, Machida H, Matsuzaki S, Bozanovic T, Pejovic T. Intersection of DNA Repair Pathways and the Immune Landscape Identifies PD-L2 as a Prognostic Marker in Epithelial Ovarian Cancer. Cancers (Basel) 2021;13:1972. [PMID: 33923934 DOI: 10.3390/cancers13081972] [Reference Citation Analysis]
93 Dai C, Lin F, Geng R, Ge X, Tang W, Chang J, Wu Z, Liu X, Lin Y, Zhang Z. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. Oncotarget. 2016;7:10332-10344. [PMID: 26871284 DOI: 10.18632/oncotarget.7243] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
94 Wachsmann MB, Pop LM, Vitetta ES. Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med. 2012;60:643-663. [PMID: 22406516 DOI: 10.231/jim.0b013e31824a4d79] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Dave K, Ali A, Magalhaes M. Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. Sci Rep 2020;10:9705. [PMID: 32546692 DOI: 10.1038/s41598-020-66257-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
96 Dodson LF, Hawkins WG, Goedegebuure P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy. 2011;3:517-537. [PMID: 21463193 DOI: 10.2217/imt.11.10] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
97 Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N, Nakajima Y. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res 2015;34:30. [PMID: 25888293 DOI: 10.1186/s13046-015-0144-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
98 Mashima E, Inoue A, Sakuragi Y, Yamaguchi T, Sasaki N, Hara Y, Omoto D, Ohmori S, Haruyama S, Sawada Y, Yoshioka M, Nishio D, Nakamura M. Nivolumab in the treatment of malignant melanoma: review of the literature. Onco Targets Ther 2015;8:2045-51. [PMID: 26273207 DOI: 10.2147/OTT.S62102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
99 Masugi Y, Nishihara R, Yang J, Mima K, da Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak JA, Liao X, Nosho K, Chan AT, Giannakis M, Bass AJ, Hodi FS, Freeman GJ, Rodig S, Fuchs CS, Qian ZR, Ogino S. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 2017;66:1463-73. [PMID: 27196573 DOI: 10.1136/gutjnl-2016-311421] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 15.7] [Reference Citation Analysis]
100 Andersen MH. Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. J Natl Cancer Inst 2015;107:djv154. [PMID: 26063792 DOI: 10.1093/jnci/djv154] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
101 McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Hum Vaccin Immunother 2016;12:563-75. [PMID: 26619245 DOI: 10.1080/21645515.2015.1093264] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
102 Muranushi R, Araki K, Yokobori T, Chingunjav B, Hoshino K, Dolgormaa G, Hagiwara K, Yamanaka T, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Harimoto N, Shimoda Y, Sano R, Oyama T, Saeki H, Shirabe K. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. Cancer Sci 2021;112:3314-23. [PMID: 34080242 DOI: 10.1111/cas.15004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Kruger S, Legenstein ML, Rösgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, Boeck S. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology 2017;6:e1310358. [PMID: 28638732 DOI: 10.1080/2162402X.2017.1310358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
104 Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res. 2017;23:1656-1669. [PMID: 28373364 DOI: 10.1158/1078-0432.ccr-16-2318] [Cited by in Crossref: 68] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
105 Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355-385. [PMID: 26883357 DOI: 10.1101/gad.275776.115] [Cited by in Crossref: 241] [Cited by in F6Publishing: 226] [Article Influence: 40.2] [Reference Citation Analysis]
106 Rosenberg A, Mahalingam D. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. J Gastrointest Oncol. 2018;9:143-159. [PMID: 29564181 DOI: 10.21037/jgo.2018.01.13] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
107 Yamamoto N, Nokihara H, Yamada Y, Shibata T, Tamura Y, Seki Y, Honda K, Tanabe Y, Wakui H, Tamura T. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Invest New Drugs 2017;35:207-16. [PMID: 27928714 DOI: 10.1007/s10637-016-0411-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
108 Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012;1:1223-1225. [PMID: 23243584 DOI: 10.4161/onci.21335] [Cited by in Crossref: 218] [Cited by in F6Publishing: 217] [Article Influence: 218.0] [Reference Citation Analysis]
109 Vucetic M, Daher B, Cassim S, Meira W, Pouyssegur J. Together we stand, apart we fall: how cell-to-cell contact/interplay provides resistance to ferroptosis. Cell Death Dis 2020;11:789. [PMID: 32968052 DOI: 10.1038/s41419-020-02994-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
110 Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014;2:361-70. [PMID: 24764583 DOI: 10.1158/2326-6066.CIR-13-0127] [Cited by in Crossref: 543] [Cited by in F6Publishing: 335] [Article Influence: 67.9] [Reference Citation Analysis]
111 Miao L, Lu Y, Xu Y, Zhang G, Huang Z, Gong L, Fan Y. PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget 2017;8:53978-88. [PMID: 28903317 DOI: 10.18632/oncotarget.9765] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
112 Cho J, Lee J, Bang H, Kim ST, Park SH, An JY, Choi MG, Lee JH, Sohn TS, Bae JM. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget. 2017;8:13320-13328. [PMID: 28076847 DOI: 10.18632/oncotarget.14519] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
113 Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol 2010;28:4045-51. [PMID: 20644090 DOI: 10.1200/JCO.2010.27.9992] [Cited by in Crossref: 115] [Cited by in F6Publishing: 88] [Article Influence: 9.6] [Reference Citation Analysis]
114 Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009;114:1545-52. [PMID: 19417208 DOI: 10.1182/blood-2009-03-206672] [Cited by in Crossref: 262] [Cited by in F6Publishing: 253] [Article Influence: 20.2] [Reference Citation Analysis]
115 Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319-334. [PMID: 25824606 DOI: 10.1038/nrclinonc.2015.53] [Cited by in Crossref: 350] [Cited by in F6Publishing: 325] [Article Influence: 50.0] [Reference Citation Analysis]
116 Lorkowski ME, Atukorale PU, Bielecki PA, Tong KH, Covarrubias G, Zhang Y, Loutrianakis G, Moon TJ, Santulli AR, Becicka WM, Karathanasis E. Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors. J Control Release 2021;330:1095-105. [PMID: 33188827 DOI: 10.1016/j.jconrel.2020.11.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
117 Enomoto K, Sho M, Wakatsuki K, Takayama T, Matsumoto S, Nakamura S, Akahori T, Tanaka T, Migita K, Ito M, Nakajima Y. Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma. Clin Exp Immunol 2012;168:186-91. [PMID: 22471279 DOI: 10.1111/j.1365-2249.2012.04565.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
118 Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G, Barilla R, Torres-Hernandez A, Hundeyin M, Mani VRK, Avanzi A, Tippens D, Narayanan R, Jang JE, Newman E, Pillarisetty VG, Dustin ML, Bar-Sagi D, Hajdu C, Miller G. γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation. Cell 2016;166:1485-1499.e15. [PMID: 27569912 DOI: 10.1016/j.cell.2016.07.046] [Cited by in Crossref: 154] [Cited by in F6Publishing: 149] [Article Influence: 25.7] [Reference Citation Analysis]
119 Fridman WH, Dieu-Nosjean MC, Pagès F, Cremer I, Damotte D, Sautès-Fridman C, Galon J. The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron. 2013;6:117-122. [PMID: 23108700 DOI: 10.1007/s12307-012-0124-9] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 7.7] [Reference Citation Analysis]
120 Liu Q, Zhao G, Zhang X, Jiang N, Zhao Z, Wang Y, Xu S, Zhu L, Lau WY, Dai G, Liu R. Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Langenbecks Arch Surg 2021. [PMID: 34518900 DOI: 10.1007/s00423-021-02321-7] [Reference Citation Analysis]
121 Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 2012;18:1611-8. [PMID: 22271878 DOI: 10.1158/1078-0432.CCR-11-1942] [Cited by in Crossref: 412] [Cited by in F6Publishing: 228] [Article Influence: 41.2] [Reference Citation Analysis]
122 Humphries MP, Hynes S, Bingham V, Cougot D, James J, Patel-Socha F, Parkes EE, Blayney JK, O'Rorke MA, Irwin GW, McArt DG, Kennedy RD, Mullan PB, McQuaid S, Salto-Tellez M, Buckley NE. Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. J Oncol 2018;2018:2937012. [PMID: 30651729 DOI: 10.1155/2018/2937012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
123 Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 2009;157:9-19. [PMID: 19659765 DOI: 10.1111/j.1365-2249.2009.03912.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 84] [Article Influence: 7.6] [Reference Citation Analysis]
124 Principe DR, Narbutis M, Kumar S, Park A, Viswakarma N, Dorman MJ, Kamath SD, Grippo PJ, Fishel ML, Hwang RF, Thummuri D, Underwood PW, Munshi HG, Trevino JG, Rana A. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy. Cancer Res 2020;80:3101-15. [PMID: 32238357 DOI: 10.1158/0008-5472.CAN-19-2959] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
125 Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015-3029. [PMID: 20008522 DOI: 10.1084/jem.20090847] [Cited by in Crossref: 1184] [Cited by in F6Publishing: 1175] [Article Influence: 91.1] [Reference Citation Analysis]
126 Goedegebuure P, Mitchem JB, Porembka MR, Tan MC, Belt BA, Wang-Gillam A, Gillanders WE, Hawkins WG, Linehan DC. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets. 2011;11:734-751. [PMID: 21599634 DOI: 10.2174/156800911796191024] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 6.6] [Reference Citation Analysis]
127 Ahmad G, Mackenzie GG, Egan J, Amiji MM. DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model. Mol Cancer Ther 2019;18:1961-72. [PMID: 31439714 DOI: 10.1158/1535-7163.MCT-18-1046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
128 Yu W, Hua Y, Qiu H, Hao J, Zou K, Li Z, Hu S, Guo P, Chen M, Sui S, Xiong Y, Li F, Lu J, Guo W, Luo G, Deng W. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis 2020;11:506. [PMID: 32632098 DOI: 10.1038/s41419-020-2701-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
129 Gao HL, Wang WQ, Yu XJ, Liu L. Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. Exp Hematol Oncol 2020;9:28. [PMID: 33101770 DOI: 10.1186/s40164-020-00184-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
130 朱晓芸, 李夏, 李素琴, 于红刚. EBV相关性胃癌研究进展. 世界华人消化杂志 2017; 25(15): 1375-1381 [DOI: 10.11569/wcjd.v25.i15.1375] [Reference Citation Analysis]
131 Myers CJ, Lu B. Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues. Int J Radiat Oncol Biol Phys 2017;99:1129-36. [PMID: 29165283 DOI: 10.1016/j.ijrobp.2017.06.2452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
132 Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73:3591-3603. [PMID: 23633484 DOI: 10.1158/0008-5472.can-12-4100] [Cited by in Crossref: 420] [Cited by in F6Publishing: 265] [Article Influence: 46.7] [Reference Citation Analysis]
133 Li L, Lu Y, Qian Z, Yang Z, Zong S, Wang Z, Cui Y. A Ti2N MXene-based nanosystem with ultrahigh drug loading for dual-strategy synergistic oncotherapy. Nanoscale 2021;13:18546-57. [PMID: 34730162 DOI: 10.1039/d1nr04008a] [Reference Citation Analysis]
134 Wang BJ, Bao JJ, Wang JZ, Wang Y, Jiang M, Xing MY, Zhang WG, Qi JY, Roggendorf M, Lu MJ, Yang DL. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol 2011; 17(28): 3322-3329 [PMID: 21876620 DOI: 10.3748/wjg.v17.i28.3322] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 85] [Article Influence: 7.6] [Reference Citation Analysis]
135 Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007;104:19458-19463. [PMID: 18042703 DOI: 10.1073/pnas.0709802104] [Cited by in Crossref: 250] [Cited by in F6Publishing: 236] [Article Influence: 16.7] [Reference Citation Analysis]
136 Upadhrasta S, Zheng L. Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune "Defects" in the Tumor Microenvironment. J Clin Med. 2019;8. [PMID: 31527414 DOI: 10.3390/jcm8091472] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
137 Piersma SJ. Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron 2011;4:361-75. [PMID: 21626415 DOI: 10.1007/s12307-011-0066-7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 5.7] [Reference Citation Analysis]
138 Lu SW, Pan HC, Hsu YH, Chang KC, Wu LW, Chen WY, Chang MS. IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models. Nat Commun. 2020;11:4611. [PMID: 32929072 DOI: 10.1038/s41467-020-18244-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
139 Ma HS, Poudel B, Torres ER, Sidhom JW, Robinson TM, Christmas B, Scott B, Cruz K, Woolman S, Wall VZ, Armstrong T, Jaffee EM. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity. Cancer Immunol Res 2019;7:428-42. [PMID: 30642833 DOI: 10.1158/2326-6066.CIR-18-0061] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 15.3] [Reference Citation Analysis]
140 Yang B, Ren H, Yu G. Case Report: Squamous Cell Carcinoma of Pancreas With High PD-L1 Expression: A Rare Presentation. Front Oncol 2021;11:680398. [PMID: 34277425 DOI: 10.3389/fonc.2021.680398] [Reference Citation Analysis]
141 Shin SP, Seo HH, Shin JH, Park HB, Lim DP, Eom HS, Bae YS, Kim IH, Choi K, Lee SJ. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. Mol Ther. 2013;21:688-695. [PMID: 23337984 DOI: 10.1038/mt.2012.252] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
142 McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M, Gribben JG. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model. Blood 2015;126:212-21. [PMID: 25979947 DOI: 10.1182/blood-2015-02-626754] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 10.4] [Reference Citation Analysis]
143 Fei Z, Deng Z, Zhou L, Li K, Xia X, Xie R. PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway. Oncol Res 2019;27:801-7. [PMID: 30982497 DOI: 10.3727/096504018X15446984186056] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
144 Shen H, Liu J, Sun G, Yan L, Li Q, Wang Z, Xie L. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients. Aging (Albany NY) 2020;13:2279-93. [PMID: 33318295 DOI: 10.18632/aging.202248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
145 Abou Khouzam R, Rao SP, Venkatesh GH, Zeinelabdin NA, Buart S, Meylan M, Nimmakayalu M, Terry S, Chouaib S. An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment. Front Immunol 2021;12:680435. [PMID: 34093582 DOI: 10.3389/fimmu.2021.680435] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Thind K, Padrnos LJ, Ramanathan RK, Borad MJ. Immunotherapy in pancreatic cancer treatment: a new frontier. Therap Adv Gastroenterol. 2017;10:168-194. [PMID: 28286568 DOI: 10.1177/1756283x16667909] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
147 Ha H, Bang JH, Nam AR, Park JE, Jin MH, Bang YJ, Oh DY. Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology. Cancer Res Treat 2019;51:832-40. [PMID: 30309223 DOI: 10.4143/crt.2018.311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
148 Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Turrini O, Raoul JL, Delpero JR, Moutardier V, Birnbaum D, Mamessier E, Bertucci F. Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget 2016;7:71198-210. [PMID: 27589570 DOI: 10.18632/oncotarget.11685] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 11.5] [Reference Citation Analysis]
149 Banerjee K, Kumar S, Ross KA, Gautam S, Poelaert B, Nasser MW, Aithal A, Bhatia R, Wannemuehler MJ, Narasimhan B, Solheim JC, Batra SK, Jain M. Emerging trends in the immunotherapy of pancreatic cancer. Cancer Lett 2018;417:35-46. [PMID: 29242097 DOI: 10.1016/j.canlet.2017.12.012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
150 Hashimoto S, Furukawa S, Hashimoto A, Tsutaho A, Fukao A, Sakamura Y, Parajuli G, Onodera Y, Otsuka Y, Handa H, Oikawa T, Hata S, Nishikawa Y, Mizukami Y, Kodama Y, Murakami M, Fujiwara T, Hirano S, Sabe H. ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. Proc Natl Acad Sci U S A 2019;116:17450-9. [PMID: 31399545 DOI: 10.1073/pnas.1901765116] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
151 Ghidini M, Lampis A, Mirchev MB, Okuducu AF, Ratti M, Valeri N, Hahne JC. Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes (Basel) 2020;12:33. [PMID: 33383713 DOI: 10.3390/genes12010033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
152 Teigler JE, Zelinskyy G, Eller MA, Bolton DL, Marovich M, Gordon AD, Alrubayyi A, Alter G, Robb ML, Martin JN, Deeks SG, Michael NL, Dittmer U, Streeck H. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection. J Virol 2017;91:e01263-17. [PMID: 28904197 DOI: 10.1128/JVI.01263-17] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
153 Fujii R, Friedman ER, Richards J, Tsang KY, Heery CR, Schlom J, Hodge JW. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget 2016;7:33498-511. [PMID: 27172898 DOI: 10.18632/oncotarget.9256] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 14.0] [Reference Citation Analysis]
154 Diana A, Wang LM, D'Costa Z, Allen P, Azad A, Silva MA, Soonawalla Z, Liu S, McKenna WG, Muschel RJ, Fokas E. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7:40992-41004. [PMID: 27329602 DOI: 10.18632/oncotarget.10038] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
155 Téglási V, Reiniger L, Fábián K, Pipek O, Csala I, Bagó AG, Várallyai P, Vízkeleti L, Rojkó L, Tímár J, Döme B, Szállási Z, Swanton C, Moldvay J. Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. Neuro Oncol 2017;19:1058-67. [PMID: 28201746 DOI: 10.1093/neuonc/now309] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
156 Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107-16. [PMID: 24217091 DOI: 10.1038/labinvest.2013.130] [Cited by in Crossref: 489] [Cited by in F6Publishing: 524] [Article Influence: 54.3] [Reference Citation Analysis]
157 Chang H, Hong JH, Lee JK, Cho HW, Ouh YT, Min KJ, So KA. Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization. J Gynecol Oncol 2018;29:e27. [PMID: 29400020 DOI: 10.3802/jgo.2018.29.e27] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
158 Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268-3277. [PMID: 20628145 DOI: 10.1182/blood-2010-05-282780] [Cited by in Crossref: 783] [Cited by in F6Publishing: 720] [Article Influence: 65.3] [Reference Citation Analysis]
159 Ansari RE, Craze ML, Althobiti M, Alfarsi L, Ellis IO, Rakha EA, Green AR. Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. Br J Cancer 2020;122:94-101. [PMID: 31819174 DOI: 10.1038/s41416-019-0626-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
160 Muenst S, Schaerli AR, Gao F, Däster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, Weber WP, Soysal SD. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014;146:15-24. [PMID: 24842267 DOI: 10.1007/s10549-014-2988-5] [Cited by in Crossref: 302] [Cited by in F6Publishing: 320] [Article Influence: 37.8] [Reference Citation Analysis]
161 Löffek S. Transforming of the Tumor Microenvironment: Implications for TGF-β Inhibition in the Context of Immune-Checkpoint Therapy. J Oncol 2018;2018:9732939. [PMID: 30631358 DOI: 10.1155/2018/9732939] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
162 Brunet LR, Hagemann T, Andrew G, Mudan S, Marabelle A. Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Oncoimmunology. 2016;5:e1112942. [PMID: 27141395 DOI: 10.1080/2162402x.2015.1112942] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
163 Cui X, Jia H, Xin H, Zhang L, Chen S, Xia S, Li X, Xu W, Chen X, Feng Y, Wei X, Yu H, Wang Y, Zhan Y, Zhu X, Zhang X. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities. Front Immunol 2021;12:778978. [PMID: 34925354 DOI: 10.3389/fimmu.2021.778978] [Reference Citation Analysis]
164 Berntsson J, Eberhard J, Nodin B, Leandersson K, Larsson AH, Jirström K. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis. Oncoimmunology 2018;7:e1465165. [PMID: 30221062 DOI: 10.1080/2162402X.2018.1465165] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
165 Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, Rotem-Yehudar R, Kufe D, Avigan D. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011;34:409-18. [PMID: 21577144 DOI: 10.1097/CJI.0b013e31821ca6ce] [Cited by in Crossref: 209] [Cited by in F6Publishing: 134] [Article Influence: 19.0] [Reference Citation Analysis]
166 Chang YL, Yang CY, Huang YL, Wu CT, Yang PC. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget 2017;8:18021-30. [PMID: 28152514 DOI: 10.18632/oncotarget.14935] [Cited by in Crossref: 24] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
167 Postow M, Callahan MK, Wolchok JD. Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J 2011;17:372-8. [PMID: 21952288 DOI: 10.1097/PPO.0b013e31823261db] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
168 Borcoman E, Le Tourneau C. Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. Ther Adv Med Oncol 2017;9:431-9. [PMID: 28607581 DOI: 10.1177/1758834017708742] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 8.6] [Reference Citation Analysis]
169 Chiavenna SM, Jaworski JP, Vendrell A. State of the art in anti-cancer mAbs. J Biomed Sci 2017;24:15. [PMID: 28219375 DOI: 10.1186/s12929-016-0311-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
170 Tarhini AA, Zahoor H, Yearley JH, Gibson C, Rahman Z, Dubner R, Rao UN, Sander C, Kirkwood JM. Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. J Transl Med. 2015;13:319. [PMID: 26419843 DOI: 10.1186/s12967-015-0678-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
171 Zhao YJ, Sun WP, Peng JH, Deng YX, Fang YJ, Huang J, Zhang HZ, Wan DS, Lin JZ, Pan ZZ. Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. Cancer Manag Res 2018;10:1-11. [PMID: 29296096 DOI: 10.2147/CMAR.S153965] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
172 Ishii H, Azuma K, Kawahara A, Matsuo N, Tokito T, Kinoshita T, Yamada K, Sasada T, Akiba J, Hoshino T. Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget 2017;8:61618-25. [PMID: 28977890 DOI: 10.18632/oncotarget.18651] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
173 Wang ZQ, Milne K, Derocher H, Webb JR, Nelson BH, Watson PH. PD-L1 and intratumoral immune response in breast cancer. Oncotarget 2017;8:51641-51. [PMID: 28881675 DOI: 10.18632/oncotarget.18305] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
174 Guo PD, Sun ZW, Lai HJ, Yang J, Wu PP, Guo YD, Sun J. Clinicopathological analysis of PD-L2 expression in colorectal cancer. Onco Targets Ther 2018;11:7635-42. [PMID: 30464512 DOI: 10.2147/OTT.S177329] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
175 Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21:24-33. [PMID: 25440090 DOI: 10.1016/j.molmed.2014.10.009] [Cited by in Crossref: 317] [Cited by in F6Publishing: 327] [Article Influence: 39.6] [Reference Citation Analysis]
176 Koo J, Hayashi M, Verneris MR, Lee-Sherick AB. Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment. Front Oncol 2020;10:581107. [PMID: 33381449 DOI: 10.3389/fonc.2020.581107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
177 Tong G, Cheng B, Li J, Wu X, Nong Q, He L, Li X, Li L, Wang S. MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells. Cancer Med 2019;8:7044-54. [PMID: 31557409 DOI: 10.1002/cam4.2542] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
178 Noh H, Hu J, Wang X, Xia X, Satelli A, Li S. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal 2015;13:14. [PMID: 25889536 DOI: 10.1186/s12964-015-0093-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
179 Fridman WH, Teillaud JL, Sautès-Fridman C, Pagès F, Galon J, Zucman-Rossi J, Tartour E, Zitvogel L, Kroemer G. The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Front Immunol 2011;2:66. [PMID: 22566855 DOI: 10.3389/fimmu.2011.00066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
180 Vucetic M, Daher B, Cassim S, Parks S, Pouyssegur J. Overcoming Therapeutic Challenges for Pancreatic Ductal Adenocarcinoma with xCT Inhibitors. Adv Exp Med Biol 2021;1301:7-24. [PMID: 34370285 DOI: 10.1007/978-3-030-62026-4_2] [Reference Citation Analysis]
181 Novak I, Yu H, Magni L, Deshar G. Purinergic Signaling in Pancreas-From Physiology to Therapeutic Strategies in Pancreatic Cancer. Int J Mol Sci 2020;21:E8781. [PMID: 33233631 DOI: 10.3390/ijms21228781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
182 Basso D, Fogar P, Falconi M, Fadi E, Sperti C, Frasson C, Greco E, Tamburrino D, Teolato S, Moz S. Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study. PLoS One. 2013;8:e54824. [PMID: 23359812 DOI: 10.1371/journal.pone.0054824] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
183 Tessier-Cloutier B, Kalloger SE, Al-Kandari M, Milne K, Gao D, Nelson BH, Renouf DJ, Sheffield BS, Schaeffer DF. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer 2017;17:618. [PMID: 28870260 DOI: 10.1186/s12885-017-3634-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
184 He J, Yi M, Tan L, Huang J, Huang L. The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer. World J Surg Oncol 2021;19:215. [PMID: 34271938 DOI: 10.1186/s12957-021-02325-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 2016;21:462-73. [PMID: 26899259 DOI: 10.1007/s10147-016-0959-z] [Cited by in Crossref: 154] [Cited by in F6Publishing: 149] [Article Influence: 25.7] [Reference Citation Analysis]
186 Mkrtichyan M, Chong N, Abu Eid R, Wallecha A, Singh R, Rothman J, Khleif SN. Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. J Immunother Cancer 2013;1:15. [PMID: 24829751 DOI: 10.1186/2051-1426-1-15] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
187 Ibrahim AM, Wang YH. Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol 2016; 22(2): 748-763 [PMID: 26811622 DOI: 10.3748/wjg.v22.i2.748] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
188 Lee VH, Lo AW, Leung CY, Shek WH, Kwong DL, Lam KO, Tong CC, Sze CK, Leung TW. Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma. PLoS One 2016;11:e0157969. [PMID: 27341634 DOI: 10.1371/journal.pone.0157969] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
189 Madorsky Rowdo FP, Baron A, Urrutia M, Mordoh J. Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. Front Immunol 2015;6:127. [PMID: 25859247 DOI: 10.3389/fimmu.2015.00127] [Cited by in Crossref: 27] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
190 Hettich M, Braun F, Bartholomä MD, Schirmbeck R, Niedermann G. High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. Theranostics. 2016;6:1629-1640. [PMID: 27446497 DOI: 10.7150/thno.15253] [Cited by in Crossref: 114] [Cited by in F6Publishing: 115] [Article Influence: 19.0] [Reference Citation Analysis]
191 Kim ST, Ha SY, Lee S, Ahn S, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim KM, Park YS. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. J Cancer. 2016;7:484-489. [PMID: 26958083 DOI: 10.7150/jca.13711] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 10.8] [Reference Citation Analysis]
192 Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6:5449-5464. [PMID: 25669979 DOI: 10.18632/oncotarget.3216] [Cited by in Crossref: 261] [Cited by in F6Publishing: 261] [Article Influence: 43.5] [Reference Citation Analysis]
193 Sehgal A, Whiteside TL, Boyiadzis M. Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opin Biol Ther 2015;15:1191-203. [PMID: 26036819 DOI: 10.1517/14712598.2015.1051028] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
194 Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A. Immunotherapy in Gastrointestinal Cancers. Biomed Res Int. 2017;2017:4346576. [PMID: 28758114 DOI: 10.1155/2017/4346576] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
195 Kunimasa K, Goto T. Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. Int J Mol Sci 2020;21:E597. [PMID: 31963413 DOI: 10.3390/ijms21020597] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
196 Hu LY, Xu XL, Rao HL, Chen J, Lai RC, Huang HQ, Jiang WQ, Lin TY, Xia ZJ, Cai QQ. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. Chin J Cancer. 2017;36:94. [PMID: 29246182 DOI: 10.1186/s40880-017-0262-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
197 Faraj SF, Munari E, Guner G, Taube J, Anders R, Hicks J, Meeker A, Schoenberg M, Bivalacqua T, Drake C, Netto GJ. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology 2015;85:703.e1-6. [PMID: 25733301 DOI: 10.1016/j.urology.2014.10.020] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 10.3] [Reference Citation Analysis]
198 Tsukamoto M, Imai K, Ishimoto T, Komohara Y, Yamashita YI, Nakagawa S, Umezaki N, Yamao T, Kitano Y, Miyata T, Arima K, Okabe H, Baba Y, Chikamoto A, Ishiko T, Hirota M, Baba H. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Cancer Sci 2019;110:310-20. [PMID: 30426611 DOI: 10.1111/cas.13874] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
199 Collins JM, Gulley JL. Product review: avelumab, an anti-PD-L1 antibody. Hum Vaccin Immunother 2019;15:891-908. [PMID: 30481100 DOI: 10.1080/21645515.2018.1551671] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
200 Xia Q, Jia J, Hu C, Lu J, Li J, Xu H, Fang J, Feng D, Wang L, Chen Y. Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma. Oncogene 2021. [PMID: 34862460 DOI: 10.1038/s41388-021-02133-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y, Chang XJ, Lu YY, Bai WL, Qu JH, Wang CP, Wang H, Lou M, Wang FS, Lv JY, Yang YP. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One. 2011;6:e23621. [PMID: 21912640 DOI: 10.1371/journal.pone.0023621] [Cited by in Crossref: 100] [Cited by in F6Publishing: 106] [Article Influence: 9.1] [Reference Citation Analysis]
202 Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol 2020; 12(2): 173-181 [PMID: 32104548 DOI: 10.4251/wjgo.v12.i2.173] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 28] [Article Influence: 15.5] [Reference Citation Analysis]
203 Shoji H, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S. The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. Oncotarget. 2017;8:95083-95094. [PMID: 29221113 DOI: 10.18632/oncotarget.18297] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
204 Cho J, Kang MS, Kim KM. Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response. J Gastric Cancer. 2016;16:1-7. [PMID: 27104020 DOI: 10.5230/jgc.2016.16.1.1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
205 Huang W, Wu Y, Qiao M, Xie Z, Cen X, Huang X, Zhao Z. CircRNA-miRNA networks in regulating bone disease. J Cell Physiol 2021. [PMID: 34796958 DOI: 10.1002/jcp.30625] [Reference Citation Analysis]
206 Xie G, Li W, Li R, Wu K, Zhao E, Zhang Y, Zhang P, Shi L, Wang D, Yin Y, Deng R, Tao K. Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells. PLoS One 2017;12:e0168822. [PMID: 28056089 DOI: 10.1371/journal.pone.0168822] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
207 Tsutaho A, Hashimoto A, Hashimoto S, Hata S, Kachi S, Hirano S, Sabe H. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer. Cell Commun Signal 2020;18:101. [PMID: 32580737 DOI: 10.1186/s12964-020-00608-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
208 Liu X, Xu D, Huang C, Guo Y, Wang S, Zhu C, Xu J, Zhang Z, Shen Y, Zhao W, Zhao G. Regulatory T cells and M2 macrophages present diverse prognostic value in gastric cancer patients with different clinicopathologic characteristics and chemotherapy strategies. J Transl Med. 2019;17:192. [PMID: 31174544 DOI: 10.1186/s12967-019-1929-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
209 Munir S, Andersen GH, Svane IM, Andersen MH. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells. Oncoimmunology 2013;2:e23991. [PMID: 23734334 DOI: 10.4161/onci.23991] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
210 Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012;62:309-35. [PMID: 22576456 DOI: 10.3322/caac.20132] [Cited by in Crossref: 255] [Cited by in F6Publishing: 233] [Article Influence: 25.5] [Reference Citation Analysis]
211 Tobias J, Steinberger P, Drinić M, Wiedermann U. Emerging targets for anticancer vaccination: PD-1. ESMO Open 2021;6:100278. [PMID: 34649221 DOI: 10.1016/j.esmoop.2021.100278] [Reference Citation Analysis]
212 Zheng P, Zhou Z. Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomark Cancer 2015;7:15-8. [PMID: 26448693 DOI: 10.4137/BIC.S29325] [Cited by in Crossref: 12] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
213 Maekawa N, Konnai S, Ikebuchi R, Okagawa T, Adachi M, Takagi S, Kagawa Y, Nakajima C, Suzuki Y, Murata S, Ohashi K. Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade. PLoS One 2014;9:e98415. [PMID: 24915569 DOI: 10.1371/journal.pone.0098415] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
214 Harvey RD. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther. 2014;96:214-223. [PMID: 24690569 DOI: 10.1038/clpt.2014.74] [Cited by in Crossref: 53] [Cited by in F6Publishing: 61] [Article Influence: 6.6] [Reference Citation Analysis]
215 Ghirelli C, Hagemann T. Targeting immunosuppression for cancer therapy. J Clin Invest 2013;123:2355-7. [PMID: 23728169 DOI: 10.1172/JCI69999] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
216 Chakravarti N, Prieto VG. Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Transl Lung Cancer Res 2015;4:743-51. [PMID: 26798583 DOI: 10.3978/j.issn.2218-6751.2015.12.10] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
217 Bocanegra A, Fernandez-Hinojal G, Zuazo-Ibarra M, Arasanz H, Garcia-Granda MJ, Hernandez C, Ibañez M, Hernandez-Marin B, Martinez-Aguillo M, Lecumberri MJ, Fernandez de Lascoiti A, Teijeira L, Morilla I, Vera R, Escors D, Kochan G. PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. Int J Mol Sci 2019;20:E1631. [PMID: 30986912 DOI: 10.3390/ijms20071631] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
218 Honda Y, Otsuka A, Ono S, Yamamoto Y, Seidel JA, Morita S, Hirata M, Kataoka TR, Takenouchi T, Fujii K, Kanekura T, Okubo Y, Takahashi K, Yanagi T, Hoshina D, Hata H, Abe R, Fujimura T, Funakoshi T, Yoshino K, Masuzawa M, Amoh Y, Tanaka R, Fujisawa Y, Honda T, Kabashima K. Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. Oncoimmunology 2017;6:e1253657. [PMID: 28197370 DOI: 10.1080/2162402X.2016.1253657] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
219 Nahas GR, Walker ND, Bryan M, Rameshwar P. A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. Breast Cancer (Auckl) 2015;9:35-43. [PMID: 26568682 DOI: 10.4137/BCBCR.S29425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
220 Lee SY, Jung DK, Choi JE, Jin CC, Hong MJ, Do SK, Kang HG, Lee WK, Seok Y, Lee EB, Jeong JY, Shin KM, Yoo SS, Lee J, Cha SI, Kim CH, Park JY. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. Sci Rep 2016;6:25952. [PMID: 27181838 DOI: 10.1038/srep25952] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
221 Rotman J, Mom CH, Jordanova ES, de Gruijl TD, Kenter GG. 'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment. BMC Cancer 2018;18:888. [PMID: 30208866 DOI: 10.1186/s12885-018-4764-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
222 Zhang M, Huang L, Ding G, Huang H, Cao G, Sun X, Lou N, Wei Q, Shen T, Xu X, Cao L, Yan Q. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. J Immunother Cancer 2020;8:e000308. [PMID: 32051287 DOI: 10.1136/jitc-2019-000308] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 20.0] [Reference Citation Analysis]
223 Jindal V, Gupta S. Expected Paradigm Shift in Brain Metastases Therapy-Immune Checkpoint Inhibitors. Mol Neurobiol 2018;55:7072-8. [PMID: 29383686 DOI: 10.1007/s12035-018-0905-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
224 Du W, Pasca di Magliano M, Zhang Y. Therapeutic Potential of Targeting Stromal Crosstalk-Mediated Immune Suppression in Pancreatic Cancer. Front Oncol 2021;11:682217. [PMID: 34290984 DOI: 10.3389/fonc.2021.682217] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
225 Natarajan A, Patel CB, Habte F, Gambhir SS. Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression. Sci Rep 2018;8:633. [PMID: 29330552 DOI: 10.1038/s41598-017-19123-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
226 Pilon-Thomas S, Mackay A, Vohra N, Mulé JJ. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 2010;184:3442-9. [PMID: 20194714 DOI: 10.4049/jimmunol.0904114] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 9.1] [Reference Citation Analysis]
227 Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7(8): 95-101 [PMID: 26306141 DOI: 10.4251/wjgo.v7.i8.95] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
228 Johansson H, Andersson R, Bauden M, Hammes S, Holdenrieder S, Ansari D. Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol 2016; 22(43): 9457-9476 [PMID: 27920468 DOI: 10.3748/wjg.v22.i43.9457] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
229 Griffiths JI, Wallet P, Pflieger LT, Stenehjem D, Liu X, Cosgrove PA, Leggett NA, McQuerry JA, Shrestha G, Rossetti M, Sunga G, Moos PJ, Adler FR, Chang JT, Sharma S, Bild AH. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proc Natl Acad Sci U S A 2020;117:16072-82. [PMID: 32571915 DOI: 10.1073/pnas.1918937117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
230 Li HB, Yang ZH, Guo QQ. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. Cell Commun Signal 2021;19:117. [PMID: 34819086 DOI: 10.1186/s12964-021-00789-w] [Reference Citation Analysis]
231 Hutcheson J, Balaji U, Porembka MR, Wachsmann MB, McCue PA, Knudsen ES, Witkiewicz AK. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease. Clin Cancer Res 2016;22:3606-17. [PMID: 26858311 DOI: 10.1158/1078-0432.CCR-15-1883] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
232 Brar G, Shah MA. The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. Therap Adv Gastroenterol 2019;12:1756284819869767. [PMID: 31516556 DOI: 10.1177/1756284819869767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
233 Silvestris N, Argentiero A, Brunetti O, Sonnessa M, Colonna F, Delcuratolo S, Luchini C, Scarpa A, Lonardi S, Nappo F, Fassan M, Solimando AG, Fucci L, Saponaro C. PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study. Expert Opin Ther Targets 2021;:1-10. [PMID: 34846251 DOI: 10.1080/14728222.2021.2011859] [Reference Citation Analysis]
234 Ikebuchi R, Konnai S, Okagawa T, Yokoyama K, Nakajima C, Suzuki Y, Murata S, Ohashi K. Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes. Immunology 2014;142:551-61. [PMID: 24405267 DOI: 10.1111/imm.12243] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
235 Knaus HA, Kanakry CG, Luznik L, Gojo I. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. Curr Drug Targets 2017;18:315-31. [PMID: 25981611 DOI: 10.2174/1389450116666150518095346] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
236 Melstrom LG, Salazar MD, Diamond DJ. The pancreatic cancer microenvironment: A true double agent. J Surg Oncol 2017;116:7-15. [PMID: 28605029 DOI: 10.1002/jso.24643] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
237 Zhuan-Sun Y, Huang F, Feng M, Zhao X, Chen W, Zhu Z, Zhang S. Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis. Onco Targets Ther 2017;10:5005-12. [PMID: 29081663 DOI: 10.2147/OTT.S146383] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
238 Zuo S, Sho M, Sawai T, Kanehiro H, Maeda K, Yoshida M, Tsukada R, Nomura M, Okuyama H. Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma. Pediatr Surg Int 2020;36:137-43. [PMID: 31925505 DOI: 10.1007/s00383-019-04616-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
239 Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529-3545. [PMID: 26185420 DOI: 10.2147/DDDT.S60328] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
240 Hamza A, Roberts D, Su S, Weber RS, Bell D, Ferrarotto R. PD-L1 expression by immunohistochemistry in salivary duct carcinoma. Ann Diagn Pathol 2019;40:49-52. [PMID: 30978575 DOI: 10.1016/j.anndiagpath.2019.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
241 Hernandez C, Arasanz H, Chocarro L, Bocanegra A, Zuazo M, Fernandez-Hinojal G, Blanco E, Vera R, Escors D, Kochan G. Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. Int J Mol Sci 2020;21:E2411. [PMID: 32244396 DOI: 10.3390/ijms21072411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
242 Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ, Xia ZJ, Huang HQ, Jiang WQ, Zhang YJ, Wang L. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol 2016;9:109. [PMID: 27737703 DOI: 10.1186/s13045-016-0341-7] [Cited by in Crossref: 112] [Cited by in F6Publishing: 116] [Article Influence: 18.7] [Reference Citation Analysis]
243 Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 2019;79:21-42. [PMID: 30560479 DOI: 10.1007/s40265-018-1033-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
244 Hall M, Liu H, Malafa M, Centeno B, Hodul PJ, Pimiento J, Pilon-Thomas S, Sarnaik AA. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer 2016;4:61. [PMID: 27777771 DOI: 10.1186/s40425-016-0164-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
245 Ott E, Bilonda L, Dansette D, Deleine C, Duchalais E, Podevin J, Volteau C, Bennouna J, Touchefeu Y, Fourquier P, El Alami Thomas W, Chetritt J, Bezieau S, Denis M, Toquet C, Mosnier JF, Jarry A, Bossard C. The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status. Oncoimmunology 2019;8:e1562834. [PMID: 30906656 DOI: 10.1080/2162402X.2018.1562834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Pan Y, Fei Q, Xiong P, Yang J, Zhang Z, Lin X, Pan M, Lu F, Huang H. Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. Oncoimmunology. 2019;8:e1581529. [PMID: 31069140 DOI: 10.1080/2162402x.2019.1581529] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
247 Roussel M, Le KS, Granier C, Llamas Gutierrez F, Foucher E, Le Gallou S, Pangault C, Xerri L, Launay V, Lamy T, Tartour E, Olive D, Fest T. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. Blood Adv 2021;5:1816-29. [PMID: 33787861 DOI: 10.1182/bloodadvances.2020003080] [Reference Citation Analysis]
248 Lee K, Hwang H, Nam KT. Immune response and the tumor microenvironment: how they communicate to regulate gastric cancer. Gut Liver. 2014;8:131-139. [PMID: 24672653 DOI: 10.5009/gnl.2014.8.2.131] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 8.3] [Reference Citation Analysis]
249 Ma K, Wei X, Dong D, Wu Y, Geng Q, Li E. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett. 2017;14:250-256. [PMID: 28693161 DOI: 10.3892/ol.2017.6105] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
250 Takahashi N, Iwasa S, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita NT, Kato K, Hamaguchi T, Yamada Y. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol 2016;142:1727-38. [PMID: 27256004 DOI: 10.1007/s00432-016-2184-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
251 Yasuda S, Sho M, Yamato I, Yoshiji H, Wakatsuki K, Nishiwada S, Yagita H, Nakajima Y. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol 2013;172:500-6. [PMID: 23600839 DOI: 10.1111/cei.12069] [Cited by in Crossref: 125] [Cited by in F6Publishing: 128] [Article Influence: 13.9] [Reference Citation Analysis]
252 Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, Liu K, Guo W. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol 2018;11:16. [PMID: 29409495 DOI: 10.1186/s13045-018-0560-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 11.3] [Reference Citation Analysis]
253 Messerschmidt JL, Prendergast GC, Messerschmidt GL. How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. Oncologist 2016;21:233-43. [PMID: 26834161 DOI: 10.1634/theoncologist.2015-0282] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
254 Lim B, Kim JH, Kim M, Kim SY. Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer. World J Gastroenterol 2016; 22(3): 1190-1201 [PMID: 26811657 DOI: 10.3748/wjg.v22.i3.1190] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
255 Kiaie SH, Sanaei MJ, Heshmati M, Asadzadeh Z, Azimi I, Hadidi S, Jafari R, Baradaran B. Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. Acta Pharm Sin B 2021;11:1083-97. [PMID: 34094821 DOI: 10.1016/j.apsb.2020.12.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
256 Ali DA, El-Guindy DM, Elrashidy MA, Sabry NM, Kabel AM, Gaber RA, Ibrahim RR, Samy SM, Shalaby MM, Salama SA, Abdelhai D. The Prognostic Significance of MACC1 Expression in Breast Cancer and Its Relationship to Immune Cells in the Tumor Microenvironment and Patient Survival. Medicina (Kaunas) 2021;57:934. [PMID: 34577857 DOI: 10.3390/medicina57090934] [Reference Citation Analysis]
257 Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561-584. [PMID: 26228759 DOI: 10.1038/nrd4591] [Cited by in Crossref: 715] [Cited by in F6Publishing: 687] [Article Influence: 102.1] [Reference Citation Analysis]
258 Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010;7:389-95. [PMID: 20514052 DOI: 10.1038/cmi.2010.28] [Cited by in Crossref: 162] [Cited by in F6Publishing: 166] [Article Influence: 13.5] [Reference Citation Analysis]
259 Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis 2015;6:e1792. [PMID: 26086965 DOI: 10.1038/cddis.2015.162] [Cited by in Crossref: 360] [Cited by in F6Publishing: 345] [Article Influence: 51.4] [Reference Citation Analysis]
260 Zhao C, Zhang W, Gong G, Xie L, Wang MW, Hu Y. A new approach to produce IgG4-like bispecific antibodies. Sci Rep 2021;11:18630. [PMID: 34545109 DOI: 10.1038/s41598-021-97393-2] [Reference Citation Analysis]
261 Zhou C, Tang J, Sun H, Zheng X, Li Z, Sun T, Li J, Wang S, Zhou X, Sun H, Cheng Z, Zhang H, Ma H. PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. Oncotarget 2017;8:58457-68. [PMID: 28938570 DOI: 10.18632/oncotarget.17022] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
262 Webb ES, Liu P, Baleeiro R, Lemoine NR, Yuan M, Wang YH. Immune checkpoint inhibitors in cancer therapy. J Biomed Res 2018;32:317-26. [PMID: 28866656 DOI: 10.7555/JBR.31.20160168] [Cited by in F6Publishing: 40] [Reference Citation Analysis]
263 Dai C, Wang M, Lu J, Dai Z, Lin S, Yang P, Tian T, Liu X, Min W, Dai Z. Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis. Onco Targets Ther 2017;10:3625-34. [PMID: 28769571 DOI: 10.2147/OTT.S138044] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
264 Huber M, Brehm CU, Gress TM, Buchholz M, Alashkar Alhamwe B, von Strandmann EP, Slater EP, Bartsch JW, Bauer C, Lauth M. The Immune Microenvironment in Pancreatic Cancer. Int J Mol Sci 2020;21:E7307. [PMID: 33022971 DOI: 10.3390/ijms21197307] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
265 Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM, Shen KH, Chen MK, Lee H, Yeh KT, Chen CJ. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS One 2015;10:e0142656. [PMID: 26562534 DOI: 10.1371/journal.pone.0142656] [Cited by in Crossref: 114] [Cited by in F6Publishing: 114] [Article Influence: 16.3] [Reference Citation Analysis]
266 Gromisch C, Qadan M, Machado MA, Liu K, Colson Y, Grinstaff MW. Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease. Cancer Res 2020;80:3179-92. [PMID: 32220831 DOI: 10.1158/0008-5472.CAN-19-2731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
267 Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 2016;44:955-72. [PMID: 27192563 DOI: 10.1016/j.immuni.2016.05.002] [Cited by in Crossref: 266] [Cited by in F6Publishing: 256] [Article Influence: 53.2] [Reference Citation Analysis]
268 Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy. Blood 2013;121:734-44. [PMID: 23223433 DOI: 10.1182/blood-2012-10-385591] [Cited by in Crossref: 103] [Cited by in F6Publishing: 105] [Article Influence: 10.3] [Reference Citation Analysis]
269 Zhou J, Jiang Y, Huang Y, Wang Q, Kaifi JT, Kimchi ET, Chabu CY, Liu Z, Joshi T, Li G. Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. Transl Oncol 2021;15:101262. [PMID: 34768100 DOI: 10.1016/j.tranon.2021.101262] [Reference Citation Analysis]
270 Danilova L, Wang H, Sunshine J, Kaunitz GJ, Cottrell TR, Xu H, Esandrio J, Anders RA, Cope L, Pardoll DM, Drake CG, Taube JM. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A 2016;113:E7769-77. [PMID: 27837027 DOI: 10.1073/pnas.1607836113] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 17.5] [Reference Citation Analysis]
271 Tan S, Chen D, Liu K, He M, Song H, Shi Y, Liu J, Zhang CW, Qi J, Yan J, Gao S, Gao GF. Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell 2016;7:866-77. [PMID: 27815822 DOI: 10.1007/s13238-016-0337-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
272 Kocikowski M, Dziubek K, Parys M. Hyperprogression Under Immune Checkpoint-Based Immunotherapy-Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model. Cancers (Basel) 2020;12:E804. [PMID: 32230745 DOI: 10.3390/cancers12040804] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
273 Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, Fujita M. Immunotherapeutic approaches for glioma. Crit Rev Immunol 2009;29:1-42. [PMID: 19348609 DOI: 10.1615/critrevimmunol.v29.i1.10] [Cited by in Crossref: 101] [Cited by in F6Publishing: 60] [Article Influence: 7.8] [Reference Citation Analysis]
274 Hong AM, Vilain RE, Romanes S, Yang J, Smith E, Jones D, Scolyer RA, Lee CS, Zhang M, Rose B. PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials. Oncotarget 2016;7:77010-20. [PMID: 27776338 DOI: 10.18632/oncotarget.12776] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
275 Thakur N, Paik KY, Hwang G, Chong Y. High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition. Diagnostics (Basel) 2021;11:597. [PMID: 33810560 DOI: 10.3390/diagnostics11040597] [Reference Citation Analysis]
276 Ramachandran P, Boyapati L, Joseph G. Scalp Metastasis as the First Presentation of an Underlying Aggressive Pancreatic Cancer. J Investig Med High Impact Case Rep 2020;8:2324709620931667. [PMID: 32525403 DOI: 10.1177/2324709620931667] [Reference Citation Analysis]
277 Iijima M, Okonogi N, Nakajima NI, Morokoshi Y, Kanda H, Yamada T, Kobayashi Y, Banno K, Wakatsuki M, Yamada S, Kamada T, Aoki D, Hasegawa S. Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma. J Gynecol Oncol 2020;31:e19. [PMID: 31912675 DOI: 10.3802/jgo.2020.31.e19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
278 Bigelow E, Bever KM, Xu H, Yager A, Wu A, Taube J, Chen L, Jaffee EM, Anders RA, Zheng L. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. J Vis Exp 2013:4059. [PMID: 23328703 DOI: 10.3791/4059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
279 Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012;2012:656340. [PMID: 22611421 DOI: 10.1155/2012/656340] [Cited by in Crossref: 193] [Cited by in F6Publishing: 190] [Article Influence: 19.3] [Reference Citation Analysis]
280 Han L, Liu F, Li R, Li Z, Chen X, Zhou Z, Zhang X, Hu T, Zhang Y, Young K, Sun S, Wen J, Zhang M. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. Oncol Lett 2014;8:1461-9. [PMID: 25202350 DOI: 10.3892/ol.2014.2356] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
281 Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother 2010;33:956-64. [PMID: 20948441 DOI: 10.1097/CJI.0b013e3181fad2b0] [Cited by in Crossref: 115] [Cited by in F6Publishing: 75] [Article Influence: 10.5] [Reference Citation Analysis]
282 Yamaki S, Yanagimoto H, Tsuta K, Ryota H, Kon M. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining. Int J Clin Oncol 2017;22:726-33. [PMID: 28314962 DOI: 10.1007/s10147-017-1112-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
283 Jiang L, Wang L, Li PF, Zhang XK, Chen JW, Qiu HJ, Wu XD, Zhang B. Positive Expression of Programmed Death ligand-1 Correlates With Superior Outcomes and Might Be a Therapeutic Target in Primary Pulmonary Lymphoepithelioma-Like Carcinoma. Onco Targets Ther. 2015;8:1451-1457. [PMID: 26109869 DOI: 10.2147/ott.s84234] [Cited by in Crossref: 8] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
284 Khomiak A, Brunner M, Kordes M, Lindblad S, Miksch RC, Öhlund D, Regel I. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers (Basel) 2020;12:E3234. [PMID: 33147766 DOI: 10.3390/cancers12113234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
285 Cavalcanti E, Armentano R, Valentini AM, Chieppa M, Caruso ML. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis. 2017;8:e3004. [PMID: 28837143 DOI: 10.1038/cddis.2017.401] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
286 Gan LL, Hii LW, Wong SF, Leong CO, Mai CW. Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Cancers (Basel) 2020;12:E1872. [PMID: 32664564 DOI: 10.3390/cancers12071872] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
287 Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21:712-720. [PMID: 25524312 DOI: 10.1158/1078-0432.ccr-14-2468] [Cited by in Crossref: 161] [Cited by in F6Publishing: 90] [Article Influence: 20.1] [Reference Citation Analysis]
288 Shibuya KC, Goel VK, Xiong W, Sham JG, Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One. 2014;9:e96565. [PMID: 24794217 DOI: 10.1371/journal.pone.0096565] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
289 Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, Johnson BD. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer 2015;3:2. [PMID: 25614821 DOI: 10.1186/s40425-014-0043-z] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 9.1] [Reference Citation Analysis]
290 Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H, Nakajima Y. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009;101:1709-16. [PMID: 19844235 DOI: 10.1038/sj.bjc.6605375] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 7.7] [Reference Citation Analysis]
291 Toss MS, Abidi A, Lesche D, Joseph C, Mahale S, Saunders H, Kader T, Miligy IM, Green AR, Gorringe KL, Rakha EA. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. Br J Cancer 2020;122:1496-506. [PMID: 32203210 DOI: 10.1038/s41416-020-0797-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
292 Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696 [PMID: 31011254 DOI: 10.3748/wjg.v25.i14.1684] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
293 Hodi FS, Dranoff G. The biologic importance of tumor-infiltrating lymphocytes. J Cutan Pathol 2010;37 Suppl 1:48-53. [PMID: 20482675 DOI: 10.1111/j.1600-0560.2010.01506.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
294 Ji M, Liu Y, Li Q, Li XD, Zhao WQ, Zhang H, Zhang X, Jiang JT, Wu CP. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med 2015;13:5. [PMID: 25592115 DOI: 10.1186/s12967-014-0373-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
295 Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D. Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. Front Immunol. 2018;9:1044. [PMID: 29868007 DOI: 10.3389/fimmu.2018.01044] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 12.3] [Reference Citation Analysis]
296 Overman M, Javle M, Davis RE, Vats P, Kumar-Sinha C, Xiao L, Mettu NB, Parra ER, Benson AB, Lopez CD, Munugalavadla V, Patel P, Tao L, Neelapu S, Maitra A. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer 2020;8:e000587. [PMID: 32114502 DOI: 10.1136/jitc-2020-000587] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 22.0] [Reference Citation Analysis]
297 Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Morisaki T, Fujita H, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M. Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. J Transl Med 2018;16:87. [PMID: 29615063 DOI: 10.1186/s12967-018-1458-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
298 Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 2011;41:2977-86. [PMID: 21710477 DOI: 10.1002/eji.201141639] [Cited by in Crossref: 108] [Cited by in F6Publishing: 97] [Article Influence: 9.8] [Reference Citation Analysis]
299 Beumer-Chuwonpad A, Taggenbrock RLRE, Ngo TA, van Gisbergen KPJM. The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer. Cells 2021;10:2234. [PMID: 34571883 DOI: 10.3390/cells10092234] [Reference Citation Analysis]
300 Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol. 2011;186:6905-6913. [PMID: 21551365 DOI: 10.4049/jimmunol.1100274] [Cited by in Crossref: 139] [Cited by in F6Publishing: 139] [Article Influence: 12.6] [Reference Citation Analysis]
301 Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol 2014;193:3835-41. [PMID: 25281753 DOI: 10.4049/jimmunol.1401572] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 15.4] [Reference Citation Analysis]
302 Looi CK, Chung FF, Leong CO, Wong SF, Rosli R, Mai CW. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res. 2019;38:162. [PMID: 30987642 DOI: 10.1186/s13046-019-1153-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 14.7] [Reference Citation Analysis]
303 Wang W, Li F, Mao Y, Zhou H, Sun J, Li R, Liu C, Chen W, Hua D, Zhang X. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet. 2013;132:641-648. [PMID: 23430453 DOI: 10.1007/s00439-013-1275.6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
304 Qu Y, Wang D, Yang L, Liu HY, Cui W, Che YQ. Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma. Mol Clin Oncol 2018;9:75-81. [PMID: 29977542 DOI: 10.3892/mco.2018.1633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
305 Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, Guo Z, Peng G, Chen G, He J, Liang W. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore) 2015;94:e515. [PMID: 25674748 DOI: 10.1097/MD.0000000000000515] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 9.1] [Reference Citation Analysis]
306 Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res 2015;21:4607-18. [PMID: 25979485 DOI: 10.1158/1078-0432.CCR-15-0200] [Cited by in Crossref: 179] [Cited by in F6Publishing: 120] [Article Influence: 25.6] [Reference Citation Analysis]
307 Singh AK, Stock P, Akbari O. Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy. 2011;66:155-162. [PMID: 20722638 DOI: 10.1111/j.1398-9995.2010.02458.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 5.5] [Reference Citation Analysis]
308 Tamai K, Nakamura M, Mizuma M, Mochizuki M, Yokoyama M, Endo H, Yamaguchi K, Nakagawa T, Shiina M, Unno M, Muramoto K, Sato I, Satoh K, Sugamura K, Tanaka N. Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma. Cancer Sci. 2014;105:667-674. [PMID: 24673799 DOI: 10.1111/cas.12406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
309 Wojtukiewicz MZ, Rek MM, Karpowicz K, Górska M, Polityńska B, Wojtukiewicz AM, Moniuszko M, Radziwon P, Tucker SC, Honn KV. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev 2021. [PMID: 34236546 DOI: 10.1007/s10555-021-09976-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
310 Rucki AA, Zheng L. Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies. World J Gastroenterol 2014; 20(9): 2237-2246 [PMID: 24605023 DOI: 10.3748/wjg.v20.i9.2237] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 71] [Article Influence: 8.9] [Reference Citation Analysis]
311 Kim HC, Choi CM. Current Status of Immunotherapy for Lung Cancer and Future Perspectives. Tuberc Respir Dis (Seoul). 2020;83:14-19. [PMID: 31905428 DOI: 10.4046/trd.2019.0039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
312 Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, Duan W, Zhou X, Liang R, Tao M. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015;6:3452-3461. [PMID: 25609202 DOI: 10.18632/oncotarget.3097] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 11.0] [Reference Citation Analysis]
313 Burmeister K, Quagliata L, Andreozzi M, Eppenberger-Castori S, Matter MS, Perrina V, Grobholz R, Jochum W, Horber D, Moosmann P, Lehmann F, Köberle D, Ng CK, Piscuoglio S, Tornillo L, Terracciano LM. Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PLoS One 2017;12:e0175563. [PMID: 28403223 DOI: 10.1371/journal.pone.0175563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
314 Lecis D, Sangaletti S, Colombo MP, Chiodoni C. Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. Cancers (Basel) 2019;11:E624. [PMID: 31060225 DOI: 10.3390/cancers11050624] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
315 Ilcus C, Bagacean C, Tempescul A, Popescu C, Parvu A, Cenariu M, Bocsan C, Zdrenghea M. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. Onco Targets Ther 2017;10:2349-63. [PMID: 28496333 DOI: 10.2147/OTT.S133385] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
316 Teixidó C, Karachaliou N, González-Cao M, Morales-Espinosa D, Rosell R. Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 2015;12:87-95. [PMID: 26175924 DOI: 10.7497/j.issn.2095-3941.2015.0019] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
317 Li X, Xu Z, Cui G, Yu L, Zhang X. BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes. Onco Targets Ther 2020;13:215-24. [PMID: 32021268 DOI: 10.2147/OTT.S232234] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
318 Salmaninejad A, Khoramshahi V, Azani A, Soltaninejad E, Aslani S, Zamani MR, Zal M, Nesaei A, Hosseini SM. PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics. 2018;70:73-86. [PMID: 28642997 DOI: 10.1007/s00251-017-1015-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
319 Harvey JB, Phan LH, Villarreal OE, Bowser JL. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol 2020;11:508. [PMID: 32351498 DOI: 10.3389/fimmu.2020.00508] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
320 Macherla S, Laks S, Naqash AR, Bulumulle A, Zervos E, Muzaffar M. Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. Int J Mol Sci 2018;19:E3505. [PMID: 30405053 DOI: 10.3390/ijms19113505] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
321 McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2013;2:662-73. [PMID: 24403232 DOI: 10.1002/cam4.106] [Cited by in Crossref: 184] [Cited by in F6Publishing: 203] [Article Influence: 20.4] [Reference Citation Analysis]
322 Wang J, Reiss KA, Khatri R, Jaffee E, Laheru D. Immune Therapy in GI Malignancies: A Review. J Clin Oncol. 2015;33:1745-1753. [PMID: 25918295 DOI: 10.1200/jco.2015.60.7879] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
323 Lin HJ, Lin J. Seed-in-Soil: Pancreatic Cancer Influenced by Tumor Microenvironment. Cancers (Basel) 2017;9:E93. [PMID: 28753978 DOI: 10.3390/cancers9070093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
324 Imai D, Yoshizumi T, Okano S, Uchiyama H, Ikegami T, Harimoto N, Itoh S, Soejima Y, Aishima S, Oda Y, Maehara Y. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Cancer Med 2017;6:1614-26. [PMID: 28602029 DOI: 10.1002/cam4.1087] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
325 Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol 2012;2012:926321. [PMID: 22500111 DOI: 10.1155/2012/926321] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
326 Hudson K, Cross N, Jordan-Mahy N, Leyland R. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Front Immunol. 2020;11:568931. [PMID: 33193345 DOI: 10.3389/fimmu.2020.568931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
327 Harada K, Ferdous T, Ueyama Y. PD-L1 expression in malignant salivary gland tumors. BMC Cancer 2018;18:156. [PMID: 29409471 DOI: 10.1186/s12885-018-4069-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
328 Andersen MH. Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology. Immunol Res 2014;60:156-64. [PMID: 25381479 DOI: 10.1007/s12026-014-8559-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
329 Wachsmann MB, Pop LM, Vitetta ES. Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med 2012;60:643-63. [PMID: 22406516 DOI: 10.2310/JIM.0b013e31824a4d79] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
330 Dai C, Geng R, Wang C, Wong A, Qing M, Hu J, Sun Y, Lo AW, Li J. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol Oncol. 2016;10:1551-1558. [PMID: 27720576 DOI: 10.1016/j.molonc.2016.09.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
331 Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, Schouten EAC, Puijk RS, de Vries JJJ, van den Tol MP, Bruynzeel AME, Streppel MM, Wilmink JW, van der Vliet HJ, Meijerink MR, Scheffer HJ, de Gruijl TD. Pancreatic Cancer and Immunotherapy: A Clinical Overview. Cancers (Basel) 2021;13:4138. [PMID: 34439292 DOI: 10.3390/cancers13164138] [Reference Citation Analysis]
332 Huang X, Zhang W, Zhang Z, Shi D, Wu F, Zhong B, Shao Z. Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis. J Cancer 2018;9:2525-31. [PMID: 30026851 DOI: 10.7150/jca.25011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
333 Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane LP, Ferris RL. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 2015;75:508-18. [PMID: 25480946 DOI: 10.1158/0008-5472.CAN-14-1215] [Cited by in Crossref: 103] [Cited by in F6Publishing: 69] [Article Influence: 12.9] [Reference Citation Analysis]
334 Feng Y, Shen J, Gao Y, Liao Y, Cote G, Choy E, Chebib I, Mankin H, Hornicek F, Duan Z. Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. Oncotarget 2015;6:11139-49. [PMID: 25871477 DOI: 10.18632/oncotarget.3576] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
335 Simeone E, Grimaldi AM, Ascierto PA. Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. Melanoma Manag 2015;2:41-50. [PMID: 30190830 DOI: 10.2217/mmt.14.30] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
336 Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, Blumenthal GM, Turner DC, Li C, Ahamadi M, de Greef R, Chatterjee M, Kondic AG, Stone JA, Booth BP, Keegan P, Rahman A, Wang Y. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn 2017;44:403-14. [PMID: 28573468 DOI: 10.1007/s10928-017-9528-y] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 12.4] [Reference Citation Analysis]
337 Zang B, Chen C, Zhao JQ. PD-1 gene rs10204525 and rs7421861 polymorphisms are associated with increased risk and clinical features of esophageal cancer in a Chinese Han population. Aging (Albany NY) 2020;12:3771-90. [PMID: 32084010 DOI: 10.18632/aging.102845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
338 Lussier DM, O'Neill L, Nieves LM, McAfee MS, Holechek SA, Collins AW, Dickman P, Jacobsen J, Hingorani P, Blattman JN. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother 2015;38:96-106. [PMID: 25751499 DOI: 10.1097/CJI.0000000000000065] [Cited by in Crossref: 103] [Cited by in F6Publishing: 73] [Article Influence: 14.7] [Reference Citation Analysis]
339 Perkhofer L, Beutel AK, Ettrich TJ. Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer. Visc Med 2019;35:28-37. [PMID: 31312647 DOI: 10.1159/000497291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
340 Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, Kleeff J, Friess H. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009;9:463. [PMID: 20035626 DOI: 10.1186/1471-2407-9-463] [Cited by in Crossref: 92] [Cited by in F6Publishing: 95] [Article Influence: 7.1] [Reference Citation Analysis]
341 Baban B, Liu JY, Qin X, Weintraub NL, Mozaffari MS. Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. PLoS One 2015;10:e0124059. [PMID: 25902191 DOI: 10.1371/journal.pone.0124059] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
342 Nakamura Y, Kobayashi T, Nishii Y, Suzuki Y, Saiki H, Ito K, Watanabe F, Nishihama K, Yasuma T, D'Alessandro-Gabazza CN, Katsuta K, Fujimoto H, Gabazza EC, Taguchi O, Hataji O. Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer. Thorac Cancer 2018;9:1476-82. [PMID: 30209885 DOI: 10.1111/1759-7714.12861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
343 Jiang F, Yu W, Zeng F, Cheng G, Xu J, Yang S, Shui Y, Wu D, Yu XF, Wei Q. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma. BMC Cancer 2019;19:503. [PMID: 31138162 DOI: 10.1186/s12885-019-5689-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
344 Lafaro KJ, Melstrom LG. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment. Am J Pathol 2019;189:44-57. [PMID: 30558722 DOI: 10.1016/j.ajpath.2018.09.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
345 Fan Y, Ma K, Wang C, Ning J, Hu Y, Dong D, Dong X, Geng Q, Li E, Wu Y. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther. 2016;9:6075-6082. [PMID: 27785054 DOI: 10.2147/ott.s115054] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
346 Lussier DM, Johnson JL, Hingorani P, Blattman JN. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer 2015;3:21. [PMID: 25992292 DOI: 10.1186/s40425-015-0067-z] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 16.1] [Reference Citation Analysis]
347 Feng Y, Jing C, Yu X, Cao X, Xu C. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1. Hematol Oncol 2020;38:467-77. [PMID: 32515093 DOI: 10.1002/hon.2758] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
348 Shen T, Zhou L, Shen H, Shi C, Jia S, Ding GP, Cao L. Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. Sci Rep. 2017;7:7848. [PMID: 28798308 DOI: 10.1038/s41598-017-08479-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
349 Dhupkar P, Gordon N, Stewart J, Kleinerman ES. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med 2018;7:2654-64. [PMID: 29733528 DOI: 10.1002/cam4.1518] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 16.3] [Reference Citation Analysis]
350 Batista S, Gregório AC, Hanada Otake A, Couto N, Costa-Silva B. The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective. J Oncol 2019;2019:6240505. [PMID: 31885581 DOI: 10.1155/2019/6240505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
351 Lim SA, Kim J, Jeon S, Shin MH, Kwon J, Kim TJ, Im K, Han Y, Kwon W, Kim SW, Yee C, Kim SJ, Jang JY, Lee KM. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019;10:496. [PMID: 31024520 DOI: 10.3389/fimmu.2019.00496] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
352 Zhu X, Zhang Q, Wang D, Liu C, Han B, Yang JM. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Cancer Biol Ther 2019;20:1105-12. [PMID: 30929569 DOI: 10.1080/15384047.2019.1595282] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
353 Park H, Bang JH, Nam AR, Eun Park J, Hua Jin M, Bang YJ, Oh DY. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. Sci Rep 2019;9:11131. [PMID: 31366979 DOI: 10.1038/s41598-019-47330-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
354 Andersen MH. The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 2014;28:1784-92. [PMID: 24691076 DOI: 10.1038/leu.2014.108] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 6.8] [Reference Citation Analysis]
355 Li C, Li W, Xiao J, Jiao S, Teng F, Xue S, Zhang C, Sheng C, Leng Q, Rudd CE, Wei B, Wang H. ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. EMBO Mol Med 2015;7:754-69. [PMID: 25851535 DOI: 10.15252/emmm.201404578] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
356 Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, Kaneda H, Iwasa T, Kawakami H, Noguchi K, Shimamoto T, Nakagawa K. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Invest New Drugs 2016;34:347-54. [PMID: 27000274 DOI: 10.1007/s10637-016-0347-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
357 Cui P, Jing P, Liu X, Xu W. Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma. Cancer Manag Res 2020;12:5893-902. [PMID: 32765090 DOI: 10.2147/CMAR.S257299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
358 Zheng Z, Bu Z, Liu X, Zhang L, Li Z, Wu A, Wu X, Cheng X, Xing X, Du H, Wang X, Hu Y, Ji J. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res 2014;26:104-11. [PMID: 24653632 DOI: 10.3978/j.issn.1000-9604.2014.02.08] [Cited by in F6Publishing: 59] [Reference Citation Analysis]
359 Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O'Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS, Noelle R. VISTA is an immune checkpoint molecule for human T cells. Cancer Res 2014;74:1924-32. [PMID: 24691993 DOI: 10.1158/0008-5472.CAN-13-1504] [Cited by in Crossref: 224] [Cited by in F6Publishing: 152] [Article Influence: 28.0] [Reference Citation Analysis]
360 Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, Viens P, Birnbaum D, van Laere S. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget 2015;6:13506-19. [PMID: 25940795 DOI: 10.18632/oncotarget.3642] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 11.8] [Reference Citation Analysis]
361 Danilova L, Ho WJ, Zhu Q, Vithayathil T, De Jesus-Acosta A, Azad NS, Laheru DA, Fertig EJ, Anders R, Jaffee EM, Yarchoan M. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. Cancer Immunol Res 2019;7:886-95. [PMID: 31043417 DOI: 10.1158/2326-6066.CIR-18-0822] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 12.7] [Reference Citation Analysis]
362 Jhaveri DT, Zheng L, Jaffee EM. Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. Semin Oncol 2014;41:559-75. [PMID: 25440603 DOI: 10.1053/j.seminoncol.2014.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
363 Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S. Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. J Gastrointest Oncol 2018;9:1014-26. [PMID: 30603120 DOI: 10.21037/jgo.2018.05.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
364 Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T, Wang Q, Jiang J. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget 2017;8:64066-82. [PMID: 28969052 DOI: 10.18632/oncotarget.19318] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
365 Martinez-Bosch N, Vinaixa J, Navarro P. Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy. Cancers (Basel) 2018;10:E6. [PMID: 29301364 DOI: 10.3390/cancers10010006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 20.5] [Reference Citation Analysis]
366 Wang W, Li F, Mao Y, Zhou H, Sun J, Li R, Liu C, Chen W, Hua D, Zhang X. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet. 2013;132:641-648. [PMID: 23430453 DOI: 10.1007/s00439-013-1275-6] [Cited by in Crossref: 90] [Cited by in F6Publishing: 96] [Article Influence: 10.0] [Reference Citation Analysis]
367 Chang CH, Shih AC, Chang YH, Chen HY, Chao YT, Hsu YC. The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis. Front Oncol 2021;11:759497. [PMID: 34868974 DOI: 10.3389/fonc.2021.759497] [Reference Citation Analysis]
368 Carosio R, Fontana V, Mastracci L, Ferro P, Grillo F, Banelli B, Canessa PA, Dessanti P, Vigani A, Morabito A, Pfeffer U, Poggi A, Roncella S, Pistillo MP. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis. J Cancer Res Clin Oncol 2021;147:459-68. [PMID: 33216211 DOI: 10.1007/s00432-020-03457-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]